secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-06-01T13:15:32+00:00
Accession:  0001104659-26-068659
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics resubmits BLA for ONS-5010 to FDA; Class 1 review, PDUFA in 60 days
--------------------------------------------------------------------------------

- Resubmitted BLA for ONS-5010 (bevacizumab-vikg) for neovascular AMD under Class 1 review.
- FDA OND concluded substantial evidence of effectiveness established; no additional trials required.
- PDUFA target decision date expected within 60 days of FDA receipt of resubmission.
- Resubmission follows successful appeal of December 2026 Complete Response Letter.
- If approved, ONS-5010 would be first FDA-approved ophthalmic formulation of bevacizumab.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926068659/0001104659-26-068659-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926068659/tm2616461d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-068659

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer